Emergent BioSolutions provides specialty products for civilian and military populations that address intentional and naturally emerging public health threats.
Employees: 201-500
Total raised: $189M
Founded date: 2006
Investors 1
| Date | Name | Website |
| - | UM Venture... | umventures... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 09.12.2015 | - | $105M | - |
| 28.07.2014 | - | $62M | - |
| 04.12.2013 | Series B | $22M | - |
Mentions in press and media 9
| Date | Title | Description |
| 10.08.2018 | Term Sheet — Friday, August 10 | MORE DEBT Happy Friday, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop According to the WSJ, the note, which accrues interest of 2.8% a year starting next September, gives WeWork the ability to foc... |
| 10.08.2018 | Emergent BioSolutions to Acquire Vaccines Company PaxVax, for $270M | Emergent BioSolutions Inc. (NYSE: EBS) is to acquire PaxVax, a company focused on specialty vaccines that protect against existing and emerging infectious diseases, for $270m. PaxVax is majority owned by an affiliate of Cerberus Capital Man... |
| 08.12.2015 | PaxVax Receives $105M Investment | PaxVax, Inc., a Redwood City, California-based specialty vaccine company, received a $105m investment. An affiliate of Cerberus Capital Management, L.P., has acquired a majority economic interest in the company. As part of the transaction, ... |
| 30.07.2014 | PaxVax Secures Up to $60M in Financing | REDWOOD CITY, CA, Specialty vaccine company focused on travel and biodefense, has closed up to $50 million in secured debt financing and $12M in an extension on its Series B. >> Click here for more funding data on PaxVax >> ... |
| 29.07.2014 | PaxVax Finds $62M For Vaccine Efforts | PaxVax, a biopharmaceuticals company developing vaccines for infectious disease, has raised $62M in a funding round. The funding included $50M in secured debt from Pharmakon Advisors, and $12M in a Series B extension round. The company is b... |
| 28.07.2014 | PaxVax Closes up to $62M in Financing | PaxVax, Inc., a Redwood City, Calif.-based specialty vaccine company focused on travel and biodefense, closed up to $62m in financing. It included an up to $50m secured debt financing from an investment fund managed by Pharmakon Advisors an... |
| 04.12.2013 | PaxVax Completes $22M Series B Financing | PaxVax Inc., a San Diego, Calif.-based developer of vaccines against infectious diseases, has completed a $22m Series B financing round. The round was led by Ignition Growth with participation from existing investor Ignition Ventures as wel... |
| 04.12.2013 | PaxVax snags $22M to get fast-tracked cholera pill through Phase III | PaxVax CEO Ken Kelley Menlo Park, CA-based PaxVax has picked up $22 million in venture cash to get an oral cholera vaccine into the FDA's hands, working its way through late-stage trials for the single-dose treatment. With the fresh funding... |
| 09.11.2009 | PaxVax Gets $2M For Oral Flu Vaccines | San Diego-based PaxVax, a firm working on orally-administered flu vaccines, has raised $2.0M out of a $6.0M funding round, according to a filing last week. Investors in the new round include Ignition Partners. According to Paxvax, its oral ... |